Find the latest news from Novozymes' news archive.
06 August 2015
Full-year profit outlook maintained. Sales growth expectations revised
18 June 2015
Every commercial trial in North America led to implementation
04 June 2015
Novozymes plans a new research center in Lyngby with space for 800 employees. The ambition is to create a global hub for biotech research and business development.
28 May 2015
The companies will develop a product based on naturally occurring microbes that can reduce antibiotic usage in poultry and brings associated health benefits.
20 May 2015
UN FAO, Roundtable on Sustainable Biomaterials, Bloomberg New Energy Finance, Carbon War Room, KLM, Novozymes and the UN Foundation partner to scale up the development and deployment of sustainable bioenergy solutions.
19 May 2015
Building on Novozymes Biopharma’s recombinant human albumin, Recombumin®, Serendex Pharmaceutical’s leading drug candidate has now entered clinical trials.
05 May 2015
The world’s first facility to produce cellulosic ethanol from sawdust will use Novozymes’ customized enzymes. With an annual capacity of 10 million liters, the plant represents an expected investment of around €40 million.
23 April 2015
Today the company raised its sales and earnings outlook for 2015 due to U.S. dollar appreciation. Currency developments in the first three months of the year have boosted Novozymes’ results. But the strength of the dollar can also have a downside.
Q1 in line with expectations; 2015 outlook adjusted for currencies
27 March 2015
Pursuant to company announcement no. 11, 2015, a reduction of the company’s B common stock by DKK 13,400,000 via cancellation of 6,700,000 treasury B stocks was adopted at the Annual Shareholders’ Meeting of Novozymes A/S on February 25, 2015.
| Copyright © 2015 Novozymes. All Rights Reserved.